You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 17, 2025

Profile for Australia Patent: 2010241571


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Australia Patent: 2010241571

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
⤷  Try for Free Apr 29, 2030 Amarin Pharms VASCEPA icosapent ethyl
⤷  Try for Free Apr 29, 2030 Amarin Pharms VASCEPA icosapent ethyl
⤷  Try for Free Apr 29, 2030 Amarin Pharms VASCEPA icosapent ethyl
⤷  Try for Free Apr 29, 2030 Amarin Pharms VASCEPA icosapent ethyl
⤷  Try for Free Apr 29, 2030 Amarin Pharms VASCEPA icosapent ethyl
⤷  Try for Free Apr 29, 2030 Amarin Pharms VASCEPA icosapent ethyl
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Comprehensive Analysis of Australian Drug Patent AU2010241571: Scope, Claims, and Patent Landscape

Overview of Key Findings

Australian patent AU2010241571, granted to Amarin Pharma Inc., protects a stable pharmaceutical composition containing ethyl-eicosapentaenoic acid (EPA), a polyunsaturated fatty acid, for treating cardiovascular diseases. The patent forms part of a global portfolio with family members in the US, Canada, Brazil, and Europe. Its claims focus on formulation stability, therapeutic applications, and methods of administration. The patent landscape reveals strategic evergreening practices, extensive international filings, and alignment with Australia’s patent linkage system, which delays generic entry.


Patent Scope and Claim Analysis

Core Inventive Elements

The patent’s inventive scope centers on:

  1. Stable EPA Formulations: Claims cover compositions where EPA constitutes ≥96% of total fatty acids, utilizing excipients like gelatin and glycerol to prevent oxidation[1][5][15].
  2. Therapeutic Applications: Methods for treating cardiovascular conditions such as hypertriglyceridemia, atherosclerosis, and heart failure via EPA administration[1][5].
  3. Dosage Regimens: Specific dosing ranges (e.g., 1–4 g/day) and administration forms (softgel capsules)[1][15].

The International Patent Classification (IPC) codes—A61K31/202 (carboxylic acids), A61P3/06 (anti-hyperlipidemics), and A61P9/00 (cardiovascular agents)—highlight its focus on lipid regulation and cardiovascular health[1][5].

Critical Claims

  • Claim 1: A pharmaceutical composition comprising ethyl-EPA, wherein EPA is ≥96% of total fatty acids, combined with antioxidants[1][15].
  • Claim 5: Use of the composition to reduce triglyceride levels in patients with hypertriglyceridemia[5].
  • Claim 10: A method of preventing cardiovascular events in patients with elevated CRP levels[15].

These claims are broad in therapeutic application but narrow in formulation specifics, potentially avoiding prior art challenges while maintaining exclusivity.


Patent Landscape and Strategic Implications

Global Family Portfolio

AU2010241571 is part of a multinational family including:

  • US 8,703,185: Granted in 2014, emphasizing stabilization techniques[1].
  • CA 2,759,284: Covers cardiovascular risk reduction in diabetic patients[5].
  • BR PI1011876: Focuses on pediatric applications[15].

This portfolio creates overlapping protections, complicating generic entry. The priority date of April 29, 2009, ensures protection until at least 2029, with possible term extensions[1][5][15].

Evergreening and Secondary Patents

The patent exemplifies evergreening through:

  • Formulation Patents: Claims on stability and bioavailability extend protection beyond the original compound[1][7].
  • Method-of-Use Patents: Specific indications (e.g., reducing CRP levels) create new exclusivity periods[15][16].
  • Combination Therapies: Later filings (e.g., EP 3,798,591) protect EPA combined with statins[15].

Australia’s patent linkage system, as outlined in the TPPA, requires generics to certify non-infringement, delaying approvals if litigation arises[4][7].


Validity and Enforcement Challenges

Written Description and Enablement

Recent cases, such as Novartis v. MSN Laboratories [12], emphasize that post-filing discoveries (e.g., EPA’s anti-inflammatory mechanisms) do not invalidate claims if the original specification enables the asserted uses. The Federal Circuit’s reversal in Novartis reinforces that broad claims supported by initial data withstand written description challenges[12].

Prior Art and Obviousness

Key prior art includes:

  • Bays et al. (2008): Demonstrated EPA’s triglyceride-lowering effects[1].
  • Aarsland et al. (1990): Studied peroxisomal β-oxidation effects of EPA[1].

However, the patent’s focus on high-purity EPA (≥96%) and stabilization methods distinguishes it from earlier formulations[1][5].


Market and Regulatory Context in Australia

IP Australia Trends (2024)

  • Domestic pharmaceutical patent filings rose 2.4%, reflecting innovation in targeted therapies[16].
  • Australia ranks second in clean energy patents, though AU2010241571 leverages cardiovascular health—a high-priority sector[16].

Therapeutic Goods Administration (TGA) Linkage

Under AUSFTA, Australia’s linkage system mandates:

  1. Patent Certification: Generics must attest to non-infringement or notify the patent holder[4][7].
  2. Automatic Injunctions: Patent disputes trigger 24-month approval stays, favoring originators[4][12].

This system has delayed generics for blockbusters like Entresto®, a precedent relevant to EPA-based therapies[12].


Competitive Landscape and Future Outlook

Key Competitors

  • Generic Manufacturers: MSN Laboratories, Teva, and Mylan face formulation challenges due to stability claims[12].
  • Innovator Firms: AstraZeneca and Pfizer hold competing omega-3 patents, but none match AU2010241571’s purity thresholds[8][14].

Litigation Risks

  • Invalidation Efforts: Generic firms may challenge claims under §138(3)(b) of the Patents Act 1990 for lack of inventive step[6][12].
  • Infringement Suits: Australia’s courts often side with patentees in preliminary injunctions, as seen in Apotex v. Sanofi[7][12].

Strategic Recommendations

  1. Portfolio Diversification: Expand into combination therapies (e.g., EPA/statins) to counter generics[15].
  2. Geographic Expansion: Leverage PCT filings via PATENTSCOPE to secure protections in emerging markets[9][14].
  3. Post-Grant Amendments: Strengthen claims using IP Australia’s opposition procedures to address prior art[6][11].

Conclusion

AU2010241571 represents a strategically crafted patent with robust formulation and therapeutic claims. Its integration into a global family portfolio, coupled with Australia’s linkage system, ensures prolonged market exclusivity for EPA-based therapies. However, validity challenges and generic competition necessitate continuous portfolio innovation and vigilant enforcement. For stakeholders, this patent underscores the importance of precision in claim drafting and the strategic use of secondary patents in maintaining competitive advantage.

"Patent landscapes are not just about counting patents; they reveal the battlegrounds of innovation." — Gevers Patent Landscape Report, 2024[13][14].

References

  1. https://pubchem.ncbi.nlm.nih.gov/patent/US8703185
  2. https://curity.io/resources/learn/scopes-vs-claims/
  3. https://learn.microsoft.com/en-us/entra/identity-platform/access-token-claims-reference
  4. https://www.citizen.org/wp-content/uploads/australia-tppa-chart.pdf
  5. https://pubchem.ncbi.nlm.nih.gov/patent/CA-2759284-A1
  6. http://manuals.ipaustralia.gov.au/patent/5.6.7.3-support-for-the-claims
  7. https://pubmed.ncbi.nlm.nih.gov/23577165/
  8. https://pharmafile.com/news/patent-analytics-study-australian-pharmaceutical-industry/
  9. https://www.wipo.int/en/web/patentscope
  10. https://www.uspto.gov/patents/search
  11. https://www.ipaustralia.gov.au/patents/search-existing-patents
  12. https://www.jdsupra.com/legalnews/federal-circuit-reverses-decision-2488855/
  13. https://gevers.eu/blog/patent-landscaping-a-full-picture-of-patents/
  14. https://www.knowmade.com/patent-landscape/
  15. https://pubchem.ncbi.nlm.nih.gov/patent/BR-PI1011876-B1
  16. https://wynnes.com.au/ip-insights/key-insights-from-ip-australias-2024-intellectual-property-report/
  17. https://onlinelibrary.wiley.com/doi/abs/10.1002/smj.925
Last updated: 2025-04-23

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.